Wegovy's Generic Brand Name and What It Means in the UK

Step 1 — know the difference between a brand name and a generic name

When a medicine is developed, it gets two names. The generic name is the scientific name of the active ingredient, in this case, semaglutide. The brand name is what the manufacturer registers commercially: Wegovy, in this instance, is Novo Nordisk's brand for the 2.4 mg (and now 7.2 mg) weekly weight-management injection.

Generics are copies of a branded medicine made by other manufacturers once the original patent expires. They contain the same active ingredient at the same dose and are subject to the same regulatory standards, but they only become legal once the patent position allows it. Wegovy's patent has not expired in the UK, which is why there is currently no licensed generic version on the market here.

It is worth reading the full explanation of Wegovy's generic name if you want a deeper breakdown of the nomenclature, because the term "generic" gets used loosely in online discussions in a way that can cause real confusion about what is actually available.

The short version: semaglutide is the generic name. Wegovy is the brand. No generic brand of Wegovy exists yet in the UK.

Step 2, understand which semaglutide brands are licensed for what

Semaglutide is sold under three brand names in the UK, and the licensing differs significantly between them. Wegovy (the weekly injection) is licensed for weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. Ozempic is also a weekly semaglutide injection, but it is licensed for type 2 diabetes, not for weight loss. Rybelsus is an oral semaglutide tablet licensed for type 2 diabetes at 3 mg, 7 mg and 14 mg doses.

There is now a fourth product: Wegovy tablets, approved by the MHRA in June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management. Its dosing schedule (1.5 mg through to a 25 mg maintenance dose) is entirely separate from Rybelsus strengths, which exist for a different indication altogether.

The semaglutide generic question is really about whether any of these products have a biosimilar or generic equivalent approved for weight management. Currently, none do. The NHS and MHRA both license medicines for specific indications: a product licensed for diabetes cannot simply be prescribed for weight loss on the basis that the molecule is the same. The NHS semaglutide information page sets out this distinction plainly.

Step 3, check what the patent timeline might mean for you

Semaglutide patents are a topic of active commercial interest globally. Several pharmaceutical companies have filed patent challenges or announced biosimilar programmes. A biosimilar is the biological equivalent of a generic, it contains the same active molecule but is manufactured by a different company and must pass its own regulatory approval before it can be dispensed.

The question of when semaglutide might go generic in the UK does not have a single answer, because different patents covering the molecule, the formulation and the device can each be challenged or expire at different times. Estimates in the pharmaceutical industry have pointed to the late 2020s as a possible window for biosimilar entry in some markets, though UK approval would require a separate MHRA process.

What that means in practical terms: if you need treatment now, the only licensed options for weight management in the UK are the branded products. If cost is a factor in your thinking, our Wegovy price comparison page gives context on what private treatment actually costs and what a legitimate price should include. A prescription medicine at an implausibly low price is usually the wrong product, the MHRA has seized large quantities of fake weight-loss pens sold online, and the risks of counterfeit products are serious.

Step 4, what this means if you're weighing up your options

Because there is no generic brand of Wegovy available, the practical choice right now is between the licensed branded products: Wegovy (injection or tablet) and Mounjaro (tirzepatide), which is a different molecule altogether. Both are prescription-only, both require clinical assessment, and a prescriber is the right person to help you decide which suits your circumstances. Our Wegovy overview covers the trial evidence, side-effect profile and eligibility criteria in full.

A question our prescribers hear regularly is whether a cheaper product described as "generic semaglutide" can be used instead. The answer is straightforward: if it does not have a UK licence for weight management and is not dispensed by a GPhC-registered pharmacy on a valid prescription, it is not a safe or legal option. That is not a technicality, it is the reason the regulatory framework exists.

If you'd like to explore whether Wegovy or another licensed treatment could be right for you, check your eligibility with our prescribers. The consultation is free, reviewed by a GPhC-registered Independent Prescriber on the same day, and there is no obligation. Our clinical team is available seven days a week if you have questions before you start.